Raymond James & Associates Guardant Health, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Guardant Health, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 13,046 shares of GH stock, worth $646,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,046

Previous 11,277 15.69%

Holding current value

$646,168

Previous $325,000 8.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$22.3 - $36.29 $39,448 - $64,197	1,769 Added 15.69%	13,046 $299,000
Q2 2024 Jul 19, 2024	SELL	$16.07 - $31.84 $94,250 - $186,741	-5,865 Reduced 34.21%	11,277 $325,000
Q1 2024 Apr 22, 2024	SELL	$17.13 - $26.91 $1.62 Million - $2.55 Million	-94,604 Reduced 84.66%	17,142 $353,000
Q4 2023 Jan 16, 2024	SELL	$21.58 - $29.5 $483,737 - $661,272	-22,416 Reduced 16.71%	111,746 $3.02 Million
Q3 2023 Oct 24, 2023	BUY	$25.8 - $39.97 $252,066 - $390,506	9,770 Added 7.85%	134,162 $3.98 Million
Q2 2023 Jul 25, 2023	SELL	$20.94 - $38.01 $83,676 - $151,887	-3,996 Reduced 3.11%	124,392 $4.45 Million
Q1 2023 Apr 14, 2023	SELL	$22.92 - $33.76 $70,501 - $103,845	-3,076 Reduced 2.34%	128,388 $3.01 Million
Q4 2022 Feb 08, 2023	SELL	$25.44 - $59.78 $505,950 - $1.19 Million	-19,888 Reduced 13.14%	131,464 $3.58 Million
Q3 2022 Oct 25, 2022	SELL	$43.66 - $61.0 $286,933 - $400,892	-6,572 Reduced 4.16%	151,352 $8.15 Million
Q2 2022 Aug 12, 2022	SELL	$28.82 - $77.35 $225,285 - $604,644	-7,817 Reduced 4.72%	157,924 $6.37 Million
Q1 2022 May 11, 2022	SELL	$48.25 - $100.49 $1.22 Million - $2.54 Million	-25,254 Reduced 13.22%	165,741 $11 Million
Q4 2021 Feb 08, 2022	SELL	$88.71 - $120.43 $778,164 - $1.06 Million	-8,772 Reduced 4.39%	190,995 $19.1 Million
Q3 2021 Nov 02, 2021	BUY	$98.77 - $132.17 $598,941 - $801,478	6,064 Added 3.13%	199,767 $25 Million
Q2 2021 Aug 11, 2021	SELL	$109.77 - $165.68 $348,739 - $526,365	-3,177 Reduced 1.61%	193,703 $24.1 Million
Q1 2021 May 14, 2021	SELL	$127.04 - $179.1 $1.6 Million - $2.25 Million	-12,573 Reduced 6.0%	196,880 $30.1 Million
Q4 2020 Feb 12, 2021	SELL	$99.96 - $135.93 $195,521 - $265,879	-1,956 Reduced 0.93%	209,453 $27 Million
Q3 2020 Nov 04, 2020	SELL	$80.32 - $111.8 $3.87 Million - $5.39 Million	-48,208 Reduced 18.57%	211,409 $23.6 Million
Q2 2020 Jul 28, 2020	BUY	$60.49 - $97.5 $236,999 - $382,005	3,918 Added 1.53%	259,617 $21.1 Million
Q1 2020 Apr 21, 2020	BUY	$59.04 - $88.81 $11.2 Million - $16.9 Million	189,906 Added 288.64%	255,699 $17.8 Million
Q4 2019 Feb 12, 2020	BUY	$59.49 - $82.78 $739,044 - $1.03 Million	12,423 Added 23.28%	65,793 $5.14 Million
Q3 2019 Nov 07, 2019	BUY	$62.59 - $110.3 $28,853 - $50,848	461 Added 0.87%	53,370 $3.41 Million
Q2 2019 Aug 06, 2019	BUY	$63.94 - $91.11 $3.05 Million - $4.35 Million	47,729 Added 921.41%	52,909 $4.57 Million
Q1 2019 May 06, 2019	BUY	$34.3 - $97.98 $177,673 - $507,536	5,180 New	5,180 $397,000

Others Institutions Holding GH

# of Institutions

393

Shares Held

121M

Call Options Held

1.43M

Put Options Held

2.37M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $5.06B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Guardant Health, Inc. Transaction History